The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms

Journal of Cardiovascular Surgery

Volumn 50, Issue 5, 2009, Pages 599-609

  Van Kuijk, J P ^a   Flu, W J ^a   Witteveen, O P ^a   Voute, M ^a   Bax, J J ^b   Poldermans, D ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aortic aneurysms, abdominal, surgery; Coronary artery disease; Review

Indexed keywords

C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; AORTA; AORTA ARCH SYNDROME; AORTA OCCLUSION; ARTERIAL STIFFNESS; ARTERY DISEASE; ARTERY INJURY; ARTERY WALL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BEHCET DISEASE; BLOOD FLOW VELOCITY; BRUCELLOSIS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DEVELOPED COUNTRY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; EHLERS DANLOS SYNDROME; ELASTOLYSIS; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GENDER; GENETIC PREDISPOSITION; GROUPS BY AGE; HEMODYNAMIC STRESS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE; MARFAN SYNDROME; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLEIOTROPY; PREVALENCE; REVIEW; SALMONELLOSIS; SMOKING; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; TUBERCULOSIS; VASCULAR ENDOTHELIUM; VASCULITIS;

AGED; AGED, 80 AND OVER; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 71049191474     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000;160:1425-1430
2. Singh K, Bonaa KH, Jacobsen BK, Bjork L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study : The Tromso Study. Am J Epidemiol 2001;154:236-244 (Pubitemid 32701159)
3. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002;346:1437-1444 (Pubitemid 34755711)
4. Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms caused by atherosclerosis? Circulation 1992;85:205-211.
5. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995;76:64C-68C.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357
7. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445
8. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322:163541.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009
10. Hall A. Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol 1994;10:31-54. (Pubitemid 24372815)
11. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-994. (Pubitemid 27485693)
12. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005;365:1577-1589
13. Wilmink TB, Quick CR, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. J Vasc Surg 1999;30:1099-105.
14. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791
15. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718 (Pubitemid 32259905)
16. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000;32:164-176
17. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430
18. Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int J Cardiol 1997;62 Suppl 2:S23-29.
19. Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 1992;107:745-749
20. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1652-9.
21. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135 (Pubitemid 28152885)
22. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719 (Pubitemid 28294580)
23. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M et al. Antioxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;154:87-96.
24. Yang Z, Kozai T, van der Loo B, Viswambharan H, Lachat M, Turina MI et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000;36:1691-1697 (Pubitemid 30826009)
25. Laufs U, Marra D, Node K, LiaoJK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999;274:21926-21931 (Pubitemid 129519746)
26. Opper C, Clement C, Schwarz H, Krappe J, Steinmetz A, Schneider J et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 1995;113:211-217
27. Vaughan CJ, Gotto AM, Jr., Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
28. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-1569 (Pubitemid 24182120)
29. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90:775-778
30. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926-933 (Pubitemid 32183796)
31. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126
32. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
33. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-1065 (Pubitemid 26125131)
34. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235 (Pubitemid 29340127)
35. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-1182
36. Powell JT, Greenhalgh RM. Clinical practice. Small abdominal aortic aneurysms. N Engl J Med 2003;348:1895-1901
37. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997;126:441-449 (Pubitemid 27114472)
38. Van Kuijk JP, Flu WJ, Dunckelgrun M, Bax JJ, Poldermans D. Coronary artery disease in patients with abdominal aortic aneurysm: a review article. J Cardiovasc Surg (Torino) 2009;50:93-107.
39. Kuivaniemi H, Shibamura H, Arthur C, Berguer R, Cole CW, Juvonen T et al. Familial abdominal aortic aneurysms: collection of 233 multiplex families. J Vasc Surg 2003;37:340-345 (Pubitemid 36236911)
40. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 2003;300:329-332
41. van Kuijk JP, Dunkelgrun M, Schreiner F, Flu WJ, Galal W, van Domburg RT et al. Preoperative oral glucose tolerance testing in vascular surgery patients: long-term cardiovascular outcome. Am Heart J 2009;157:919-925
42. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
43. Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health 2004;14:343-349 (Pubitemid 40186442)
44. MacSweeney ST, Young G, Greenhalgh RM, Powell JT. Mechanical properties of the aneurysmal aorta. Br J Surg 1992;79:1281-1284
45. McCormick ML, Gavrila D, Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2007;27:461-469 (Pubitemid 46263388)
46. Hobbs SD, Claridge MW, Quick CR, Day NE, Bradbury AW, Wilmink AB. LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003;26:618-622 (Pubitemid 37461777)
47. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol 2000;151:575-583 (Pubitemid 30463602)
48. Alcorn HG, Wolfson SK, Jr., Sutton-Tyrrell K, Kuller LH, O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1996;16:963-970 (Pubitemid 26266894)
49. Tornwall ME, Vutamo J, Haukka JK, Albanes D, Huttunen JK. Lifestyle factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. Epidemiology 2001;12:94-100. (Pubitemid 32006468)
50. Rodin MB, Daviglus ML, Wong GC, Liu K, Garside DB, Greenland P et al. Middle age cardiovascular risk factors and abdominal aortic aneurysm in older age. Hypertension 2003;42:61-68 (Pubitemid 36842237)
51. Lindblad B, Borner G, Gottsater A. Factors associated with development of laige abdominal aortic aneurysm in middle-aged men. Eur J Vasc Endovasc Surg 2005;30:346-352 (Pubitemid 41258491)
52. Wanhainen A, Bergqvist D, Boman K, Nilsson TK, Rutegard J, Bjorck M. Risk factors associated with abdominal aortic aneurysm: a population-based study with historical and current data. J Vasc Surg 2005;41:390-396 (Pubitemid 40523577)
53. Iribarren C, Darbinian JA, Go AS, Fireman BH, Lee CD, Grey DP. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. Ann Epidemiol 2007;17:669-678 (Pubitemid 47277510)
54. Simoni G, Pastorino C, Perrone R, Ardia A, Gianrossi R, Decian F et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg 1995;10:207-10.
55. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999;29:122-7; discussion 127-129
56. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation. 2001;103:2260-2265 (Pubitemid 32433715)
57. Curci JA, Thompson RW. Adaptive cellular immunity in aortic aneurysms: cause, consequence, or context? J Clin Invest 2004;114:168-171
58. Annabi B, Shedid D, Ghosn P, Kenigsberg RL, Desrosiers RR, Bojanowski MW et al. Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. J Vasc Surg 2002;35:539-546 (Pubitemid 44718601)
59. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999;100:48-54.
60. Wilson WR, Evans J, Bell PR, Thompson MM. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005;30:259-62.
61. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-1678 (Pubitemid 28521054)
62. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137 Suppl:S101-109.
63. Ganne F, Vasse M, Beaudeux JL, Peynet J, Francois A, Mishal Z et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase- receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb Haemost 2000;84:680-688 (Pubitemid 30798953)
64. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000;59:245-254
65. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001;69:959-62.
66. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-283 (Pubitemid 32095415)
67. Nagasnima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002;36:158-63. (Pubitemid 41122905)
68. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-775 (Pubitemid 36566165)
69. Ejiri J, Inoue N, Tsukube T, Munezane T, Hino Y, Kobayashi S et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003;59:988-996 (Pubitemid 38366255)
70. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005;241:92-101. (Pubitemid 40040997)
71. Kalyanasundaram A, Elmore JR, Manazer JR, Golden A, Franklin DP, Gait SW et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006;43:117-124
72. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrun M et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006;32:21-26 (Pubitemid 43842752)
73. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006;97:279-280 (Pubitemid 43139252)
74. Mosorin M, Niemela E, Heikkinen J, Lahtinen J, Tiozzo V, Sana J et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg 2008;7:578-581
75. Schlosser FJ, Tangelder MJ, Verhagen HJ, van der Heijden GJ, Muhs BE, van der Graaf Y et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008;47:1127-1133
76. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-654.
77. Pleumeekers HJ, Hoes AW, van der Does E, van Urk H, Hofman A, de Jong PT et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Am J Epidemiol 1995;142:1291-1299 (Pubitemid 26006428)
78. Evans J, Powell JT, Schwalbe E, Loftus IM, Thompson MM. Simvastatin attenuates the activity of matrix metailoprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 2007;34:302-303 (Pubitemid 47194427)